Grant Funds Development of a Novel Malaria Vaccine - - BioPharm International

ADVERTISEMENT

Grant Funds Development of a Novel Malaria Vaccine



iQur, the UK biotechnology company, and the Edward Jenner Institute for Vaccine Research (University of Oxford) announced that that they will receive a grant of £152,000 ($201,523) from the Technology Strategy Board’s Biocatalyst fund to develop a novel malaria vaccine. The parties to develop a novel virus-like particle (VLP) based vaccine using iQur’s proprietary tandem core technology.

A proof of concept study will be carried out in which iQur will make VLPs carrying specific malaria targets that have been identified by the Jenner. If the project is successful, further funding will be sought to progress the targets into a clinical trial.

Source: iQur

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here